Multiple Myeloma is cancer that forms in a type of white blood cell called a plasma cell. Healthy plasma cells help you fight infections by making antibodies that recognize and attack germs. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells.
The Multiple Myeloma Market size across the 8MM i.e. the United States, Eu5(the UK, Germany, France, Italy, Spain), China, and Japan, was $16.27bn in 2019 and is increasing with a modest CAGR during the study period (2018-2030), according to DelveInsight, a leading company in healthcare analytics and consulting.
Some key highlights from the Multiple Myeloma report:
The total Multiple Myeloma incident cases are expected to reach 91,520 in 2020 in the 8MMHigher usage of bortezomib based regimen observed across the US, Japan and EU5; Bortezomib + Lenalidomide + dex regimen is the preferred treatment choice in the US and Japan in the first-line compared to Bortezomib + Melphalan ± Prednisone and Bortezomib + dex regimen in EU5. In the case of China, higher usage of thalidomide based regimen found in the first-line settingKey Companies like GlaxoSmithKline, Bristol-Myers Squibb, Merck Sharp & Dohme Corp., Pfizer, Takeda, AbbVie, Roche, Janssen Research & Development, Amgen, AstraZeneca, etc. are fuelling the Multiple Myeloma market size growth.Patent expiry of multiple blockbuster drugs like Darzalex, Revlimid, Pomalyst, and Kyprolis is on the lines to expire from 2026 onwards, and this will erode the sales value significantly and the market is expected to decline from 2028 onwards due to cumulative impacts of patent expiry.Multiple Myeloma Key Players: Kiadis Pharma, CASI Pharmaceuticals, NOXXON Pharma, MorphoSys), Sana Biotechnology, Ayala Pharmaceuticals, Cellectar Biosciences, Bristol-Myers Squibb, Poseida Therapeutics, AbbVie/Genentech, Janssen Research and Development, Nanjing Legend Biotech, Genenta Science, Biotest AG, Teneobio, iCell Gene Therapeutics, Juno Therapeutics, Arch Oncology, Regeneron Pharmaceuticals, Incyte Corporation, NexImmune Inc., Chongqing Precision Biotech, Novartis, CASI Pharmaceuticals, Ionis Pharmaceuticals, AgenTus Therapeutics, Biohaven Pharmaceuticals, CRISPR Therapeutics, Pfizer, GlaxoSmithKline, Seagen Inc., Heidelberg Pharma, Bluebird Bio, C4 Therapeutics, Inc., Hoffmann-La Roche, Phosplatin Therapeutics, Arcellx, Inc., HitGen Inc., Boehringer Ingelheim, I-Mab Biopharma, Celyad Oncology, Amgen and others
Key Multiple Myeloma Pipeline Therapies: TNB-383B, ONC201, AO-176, JCARH125, REGN5458, INCB001158, TAK-573, NEXI-002 T Cells, PHE885, CID-103, ION251, EMB-06, agenT-797, CTX120, PF-06863135, SEA-BCMA, AEVI-007, HDP-101, bb21217, CFT7455, RO7425781, PT-112, HG146, CYAD-211, AMG 701, Nivolumab, ventoclax, RAPA-201 autologous T cells, K NK004, CID 103, NOX-A12, TJ202, APG-2575, AL 102, CLR 131 and others.
Scope of the Report
Geography Covered: 8MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.
Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).
Markets Segmentation: By Geographies, By Therapies (Forecasted + Historical).
Companies Covered
Analysis: Comparative and conjoint analysis of emerging therapies, Attribute Analysis
Case Studies
KOL's Views
Analyst's View
Other Reports:
Corneal Endothelial Dystrophy Market
Higher-Risk Chronic Myelomonocytic Leukemia Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Sign in to leave a comment.